Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - immunoglobulin - normal; normal immunoglobulin -

Canadà - anglès - Health Canada

takeda canada inc - immunoglobulin (human) - solution - 200mg - immunoglobulin (human) 200mg - serums

Estats Units - anglès - NLM (National Library of Medicine)

california department of public health - human botulinum neurotoxin a/b immune globulin (unii: x641y30oa7) (human botulinum neurotoxin a/b immune globulin - unii:x641y30oa7) - human botulinum neurotoxin a/b immune globulin 50 mg in 1 ml - babybig® , botulism immune globulin intravenous (human), is indicated for the treatment of infant botulism caused by toxin type a or b in patients below one year of age. - as with other immunoglobulin preparations, babybig should not be used in individuals with a prior history of severe reaction to other human immunoglobulin preparations.[1-4] - individuals with selective immunoglobulin a deficiency have the potential for developing antibodies to immunoglobulin a and could have anaphylactic reactions to the subsequent administration of blood products that contain immunoglobulin a. babybig has been studied for safety and efficacy only in patients below one year of age [see adverse reactions (6) and clinical studies (14) ]. it has not been tested in other populations. ndc 68403-1100-7 rx only 100 mg igg, 100 mg sucrose 20 mg albumin (human) lyophilized solvent detergent treated botulism immune globulin intravenous (human) (big-iv) babybig® store between 2°c and 8°c (35.6°f and 46.4°f).

Canadà - anglès - Health Canada

gilead sciences canada inc - axicabtagene ciloleucel - suspension - 200000000cells - axicabtagene ciloleucel 200000000cells - antineoplastic agents